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• Encouraging healthy behaviors






PATH is working in countries shaded orange.



























Malaria:  market opportunity?
 Each year 350–500 million cases of malaria occur worldwide
 Over one million people die, most of them young children in sub-
Saharan Africa 
 In 2002, malaria was the fourth cause of death in children in 
developing countries.
Source: United States Centers for Disease Control
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PATH & GSK: RTS,S malaria vaccine
 Background
 GlaxoSmithKline Biologicals (GSK) created RTS,S 
vaccine candidate in 1987 in close collaboration with 
Walter Reed Army Institute of Research
 In 2001 GSK and the PATH Malaria Vaccine Initiative 
(MVI) formed PDP with support from the Bill & Melinda 
Gates Foundation
 Goal
 Develop vaccine for infants and young children, with a 
geographic focus on sub-Saharan Africa
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RTS,S malaria vaccine status – Phase 2
Phase 2 clinical trials completed March 2007
 Favorable safety 
profile (9000 doses 
to 3000 infants and 
children)
 Can be co-
administered within 
the infant EPI 
immunization 
schedule
 Beneficial effect on clinical and severe disease over 
42 months
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• Expertise in developing           
country health systems
• Presence in poor countries







• Expertise in product 
development
• Scientific and technical 
capacity
• Intellectual property  
• Manufacturing facilities & 
equipment
• Large-scale distribution 
systems
• Market-based approach













Drivers of partnership diversity
Less certainMore certain







Global access: critical terms
 Ensuring product supply
 Impact requires scale
 Making products affordable
 Market segmentation 
enables tiered pricing 
structures
 Managing intellectual 
property
 Relative value of supply and 
price concessions vs royalties














 GSK to supply and provide preferred pricing for infants 
and children in malaria-endemic regions of Africa
 MVI to research and project demand in Africa
 MVI and GSK work together with government and other 
partners to ensure that clinical trials adhere to the 
highest clinical, ethical, and safety standards.
Case: RTS,S malaria vaccine
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PATH Meningitis Vaccine Project (MVP)
 Background
 Created in June 2001 by a grant from the Bill & 
Melinda Gates Foundation as a 10-year partnership 
between WHO and PATH
 Goal
 Eliminate epidemic meningitis as a public health 
problem in Sub-Saharan Africa through the 
development, testing, licensure and widespread 
use of conjugate meningococcal vaccines
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MVP Men A vaccine development model
24
Men A conjugate vaccine- “MenAfriVac”
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MVP status
MenAfriVacTM, the Men A Conjugate Vaccine (PsA-TT) 
developed by MVP & Serum Institute of India has shown:
Equivalent safety profile to the licensed polysaccharide
and Hib vaccines in 1-29 year-olds in Africa and India
The characteristics of a conjugate vaccine:
 Superior immunogenicity (rSBA & hSBA) in 12-23 month 
olds vs. the licensed polysaccharide vaccine
 Effective inducement of immunological memory in 12-23 
month olds
 Inducement of bactericidal antibodies persisting at sustained 
levels in 12-23 month olds vs. polysaccharide vaccine
 Superior immunogenicity (rSBA) confirmed in 2-29 year olds 




 Single dose in catch up vaccination campaigns for 1 
to 29 year olds to rapidly induce herd immunity
 Start with Burkina Faso, Mali and Niger
 Other belt countries are prioritized on the basis of 
epidemiologic need and absorptive capacity
 Protect birth cohorts
 Single dose at 9-12 months or two doses (14 
weeks and 9 months) within the EPI schedule
or
 Follow-up campaigns targeted at 1-4 year olds 
every 5 years
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MVP 2010 timelines for introduction
 Market authorization by the Indian National 
Regulatory Agency in Q1 2010
 WHO Prequalification expected by mid-
2010 (fast track)
 Introduction in Burkina Faso, Mali, and 
Niger in Q4 2010
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Case: Men A conjugate vaccine
Less certainMore certain
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Case: Men A conjugate vaccine
 Partnership terms
 Serum Institute of India to supply guaranteed 
volume vaccine/year at USD<.50/dose
 WHO to assist in registration activities in Sub-
Saharan Africa
 WHO to assist in vaccine introduction activities 
in Sub-Saharan Africa
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Case: Japanese Encephalitis Vaccine
 Background
 Efforts to control vector, the Culex mosquito, have been 
ineffective
 Inactivated vaccine exists, but cost out of reach for 
public sector programs; millions of children at risk
 Chengdu Institute of Biological Products had 
manufactured improved vaccine to protect over 200 
million children in China over a 20-year period
 Goal
 Ensure equitable access to a safe, efficacious vaccine
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More riskLess risk










 CDIBP caps public-sector price until 2026 for low-
income countries; gains access to international 
markets
 PATH builds evidence base for use by collecting data 
required for country-by-country licensure and eventually 
for WHO prequalification
 Collaboration supports construction of new facility to 
ensure sufficient, sustainable, and affordable supply. 
PATH provides technical assistance to confirm that 
equipment, installation and production meet global 
standards
Case: Japanese Encephalitis Vaccine
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Product development partnerships and 
global access
 Expand the risk/return 
threshold for the private 
sector
 Identify unique partnership 
characteristics























 Vaccines represent one of the most successful 
and cost-effective public health interventions 
available today.
 Millions of children remain underimmunized or 
unimmunized because of the shortage of 
affordable and available vaccines.
 PATH is working to close the immunization gap by 
partnering to develop new vaccines and ensuring 
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